Dear Shareholders,Happy Lunar New Year from all of us at Team...

Dear Shareholders, Happy Lunar New Year from all of us at Team Imugene! We have great expectations for 2022 and January has been a very busy month with three significant announcements just this last week. The three announcements are as follows; Clinical Trial Supply Agreement with Imugene and Roche to Evaluate PD1-Vaxx in Combination with an Immune Checkpoint Inhibitor for Treatment of Lung Cancer, click here HER-Vaxx Immunotherapy Patent Granted in Europe, click here Oncolytic Virotherapy CF33 Patent Granted in Japan, click here Last Friday we announced a new clinical trial supply agreement with Roche to evaluate the safety and efficacy of Imugene’s PD1-Vaxx, a B-cell activating immunotherapy, in combination with atezolizumab (Tecentriq®), an immune checkpoint inhibitor targeting PD-L1, in patients with non-small cell lung cancer (NSCLC). I'm excited to be partnering with my former program and company Genentech/Roche for this combination. It’s an outstanding accomplishment to see us collaborate with Roche, in combination with our PD1-Vaxx drug. PD1-Vaxx has shown a tolerable safety profile and encouraging efficacy in patients with NSCLC, and we are looking forward to evaluating PD1-Vaxx with atezolizumab in ICI treatment-naïve and pretreated NSCLC patients. Also last Friday, we received a Notice of Grant from the European Patent Office for Patent Application number 16779340.5 (granted patent number 1111/3283105) which protects our HER-Vaxx immunotherapy, currently in development for HER-2 positive gastric cancer. Just importantly, today we announced we have received a Notice of Grant from the Japanese Patent Office for Patent Application number 2019-507161 which protects its oncolytic virotherapy CF33, including VAXINIA (CF33-hNIS) and CHECKVacc (CF33-hNIS-antiPDL1). Imugene receiving this patent grant for the CF33 family of oncolytic viruses from the Japanese patent office is a crucial step forward and is the first of many expected patent grants from multiple countries. The start of our VAXINIA and CHECKVacc OV studies are a significant milestone for clinicians treating patients faced with the challenge of solid tumour cancers. I am personally exuberant about the transformational opportunities we are developing and the team we are assembling in 2022. I encourage you to continue to follow our progress. As always, many thanks for your enduring support. Kindest regards, Leslie